Transcript profiling distinguishes complete treatment responders with locally advanced cervical cancer.

ABSTRACT: Cervical cancer (CC) mortality is a major public health concern since it is the second cause of cancer-related deaths among women. Patients diagnosed with locally advanced CC (LACC) have an important rate of recurrence and treatment failure. Conventional treatment for LACC is based on chemotherapy and radiotherapy; however, up to 40% of patients will not respond to conventional treatment; hence, we searched for a prognostic gene signature able to discriminate patients who do not respond to the conventional treatment employed to treat LACC. Tumor biopsies were profiled with genome-wide high-density expression microarrays. Class prediction was performed in tumor tissues and the resultant gene signature was validated by quantitative reverse transcription-polymerase chain reaction. A 27-predic

SUBMITTER: Fernandez-Retana J 

PROVIDER: S-EPMC4415118 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature